Immunome, Inc. (NASDAQ:IMNM) Receives $31.50 Consensus Target Price from Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM) have been assigned a consensus rating of “Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have covered the stock in the last year is $32.67.

IMNM has been the subject of a number of analyst reports. Guggenheim initiated coverage on shares of Immunome in a research report on Monday. They issued a “buy” rating and a $35.00 price objective for the company. Leerink Partnrs reissued an “outperform” rating on shares of Immunome in a research report on Monday, January 29th. SVB Leerink initiated coverage on shares of Immunome in a research report on Monday, January 29th. They issued an “outperform” rating and a $30.00 price objective for the company. Finally, Wedbush lifted their price objective on shares of Immunome from $27.00 to $33.00 and gave the company an “outperform” rating in a research report on Monday, April 1st.

Institutional Trading of Immunome

Several hedge funds and other institutional investors have recently modified their holdings of IMNM. Vanguard Group Inc. boosted its holdings in shares of Immunome by 339.0% during the 4th quarter. Vanguard Group Inc. now owns 1,740,026 shares of the company’s stock worth $18,618,000 after buying an additional 1,343,697 shares during the period. Avidity Partners Management LP acquired a new stake in Immunome in the 4th quarter worth about $14,268,000. Price T Rowe Associates Inc. MD raised its stake in Immunome by 505.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,051,222 shares of the company’s stock worth $11,249,000 after purchasing an additional 877,592 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Immunome in the 2nd quarter worth about $3,307,000. Finally, TD Asset Management Inc acquired a new stake in Immunome in the 3rd quarter worth about $1,063,000. Institutional investors own 44.58% of the company’s stock.

Immunome Price Performance

Shares of IMNM opened at $17.38 on Monday. The firm has a 50-day moving average of $23.16 and a 200-day moving average of $14.80. Immunome has a one year low of $4.44 and a one year high of $30.96. The company has a market cap of $1.04 billion, a PE ratio of -3.22 and a beta of 1.66.

About Immunome

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.